$YDES

YD Bio (Nasdaq: YDES) and EG BioMed launched an AI-based cancer risk assessment tool for 10 cancer types, priced at $10 during promotion. The tool uses a health survey and AI models to provide personalized risk stratification and screening guidance. YD Bio plans to merge with EG BioMed, subject to approvals. The assessment is not intended for diagnosis but aims to facilitate discussions with healthcare professionals.

Shen Ethan PhD (CEO) purchased 12,700 shares of YD Bio Ltd (YDES) at $3.85 on 2026-09-14.

Shen Ethan PhD (CEO) purchased 3,100 shares of YD Bio Ltd (YDES) at $3.93 on 2026-09-09.

Shen Ethan PhD (CEO) purchased 18,378 shares of YD Bio Ltd (YDES) at $3.67 on 2026-09-04.

YD Bio Ltd (YDES) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026 TAIPEI, Taiwan, Aug. 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detec

After-hours gainers included Profusa (PFSA) after a 1-for-4 reverse split, with shares outstanding cut to about 605,726. INVO Fertility (IVF) rose after Q2 results: revenue about $2.2M (+17% YoY) and net income about $0.9M. Amylyx (AMLX) traded higher ahead of Phase 3 LUCIDITY topline results on Aug 18, 2026. Vogenx (VOGX) and others also gained.

Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.

YD Bio Limited (Nasdaq: YDES) said its affiliate EG BioMed US obtained out-of-state CLIA/CAP laboratory licenses in Rhode Island (clinical genetics, issued May 13, 2026) and Pennsylvania (clinical chemistry/hematology, issued June 9, 2026). The Bothell, Washington lab’s footprint now covers 46 states plus DC and Guam, supporting blood-based early cancer detection testing via its telehealth platform.

YD Bio Limited has announced the launch of its EG Telehealth Platform in collaboration with EG BioMed Co., Ltd., expanding cancer detection and monitoring services across 44 U.S. states, Washington, D.C., and Guam. This platform combines YD Bio's digital health infrastructure with EG BioMed's laboratory capabilities to screen for various cancers, including pancreatic, colorectal, liver, gastrointestinal, and breast cancers. The launch is a step towards scalable deployment, coinciding with YD Bio's ongoing plans to merge with EG BioMed and recent acquisitions to enhance its technological capabilities.

YD Bio Ltd director Lee Jerry Yin-Chia has filed a Form 3 insider report for YDES, indicating no reported purchases, sales, or other insider transactions. The filing lists him as a director, with all transaction counts and share totals recorded as zero. This Form 3 filing confirms no insider trading activity from the specified director.